Medicus Pharma announced positive FDA feedback and central IRB approval for its optimized Phase 2 study of Teverelix, a long-acting GnRH antagonist, targeting men after a first episode of acute urinary retention (AUR). The redesigned study will enroll about 126 patients, down from the previously planned 390, aiming to generate early pharmacodynamic data and support dose and route optimization. FDA recommendations are operational and do not affect the study's scientific goals. This streamlined approach is expected to accelerate development, optimize capital use, and provide robust data to guide future regulatory and clinical decisions.
Citizens Community Bancorp, Inc. reported a Q2 earnings per share (EPS) of $0.11, significantly missing analyst expectations of $0.41, marking a 73.17% earnings surprise. The company's revenue also fell short at $16.11 million, slightly down from las...
Rambus Inc. is poised for growth in the AI memory market as it prepares to release its quarterly earnings report. Analysts expect an EPS of $0.72 and revenue around $199.3 million, up from $180.19 million last quarter, driven by increased demand for ...
Alliance Resource Partners reported Q2 revenue of $551.6 million, slightly below estimates, due to lower coal prices despite higher sales volumes. The company saw a 33.9% rise in net income to $79.6 million, supported by strong oil and gas royalties....
Welltower is set to report strong Q2 revenue growth of about $3.43 billion, a 34.5% increase year-over-year, reflecting robust demand in healthcare real estate. Earnings per share estimates vary widely, from $0.64 to $1.55, indicating uncertainty in ...
Christian Dior reported strong first-half 2026 results with €38.6 billion in sales and an operating profit of €8.7 billion, maintaining a high operating margin of 22.5%. The group saw a 3% organic sales growth in Q2, driven by strong performances in ...
